Candriam SCA’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Candriam SCA’s Portfolio SRRA Stock Details SRRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-36,683	Closed	-$2.02M	–	910
2022 Q2	$2.02M	Buy	+36,683	New	+$1.92M	0.02%	507
2019 Q2	–	Sell	-18,000	Closed	-$1.23M	–	849
2019 Q1	$1.23M	Hold	18,000	–	–	0.02%	589
2018 Q4	$950K	Hold	18,000	–	–	0.01%	590
2018 Q3	$1.22M	Hold	18,000	–	–	0.02%	586
2018 Q2	$2.13M	Hold	18,000	–	–	0.03%	471
2018 Q1	$1.49M	Buy	18,000 +3,000	+20%	+$340K	0.03%	530
2017 Q4	$2.24M	Buy	+15,000	New	+$1.44M	0.04%	429
2016 Q1	–	Sell	-1,780	Closed	-$1.07M	–	658
2015 Q4	$1.07M	Hold	1,780	–	–	0.03%	379
2015 Q3	$1.46M	Buy	+1,780	New	+$2.01M	0.04%	385

Other funds holding SRRA

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Candriam SCA's SRRA Position: Q3 2022 in Review

Candriam SCA sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 36,683 shares — an estimated $2.02M sold.

Candriam SCA first reported a position in SRRA in Q3 2015 and held it in 9 quarters. The position peaked at $2.24M in Q4 2017. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.

Candriam SCA reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Candriam SCA sold 36,683 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $2.02M.
Candriam SCA first reported a position in Sierra Oncology, Inc. Common Stock in Q3 2015 and held it in 9 quarters.
Candriam SCA's Sierra Oncology, Inc. Common Stock position peaked at $2.24M in Q4 2017.
1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.

Based on Candriam SCA's 13F filing for Q3 2022, filed 10 Nov 2022.